Could a skin gel help fight breast cancer? early trial tests endoxifen

NCT ID NCT03317405

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a gel form of the drug endoxifen, applied to the skin, in 32 women scheduled for breast surgery. The goal is to see if the gel is safe and how much of the drug gets into breast tissue and blood. If successful, it might offer a gentler way to treat or prevent breast cancer in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
endoxifen hydrochloride gel
What this could lead to
If it works, this could lead to a topical treatment that lowers breast cancer risk or helps manage early-stage disease without the side effects of pills.
What could go wrong
This is a very early (Phase 1) trial with only 32 participants, so it primarily checks safety and dosing. It may not show any benefit against cancer, and skin irritation at the application site is a possible risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CARCINOMA IN SITU are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cedars-Sinai Medical Center

    Los Angeles, California, 90048, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.